SUBOXONE® is the first opioid medication approved under DATA 2000 for the treatment of opioid dependence in an office-based setting. SUBOXONE® also can be dispensed for take-home use, just as any other medicine for other medical conditions.The primary active ingredient in SUBOXONE® is buprenorphine.Because buprenorphine is a partial opioid agonist, its opioid effects are limited compared with those produced by full opioid agonists, such as oxycodone or heroin. SUBOXONE® also contains naloxone, an opioid antagonist.The naloxone in SUBOXONE® is there to discourage people from dissolving the tablet and injecting it. When SUBOXONE® is placed under the tongue, as directed, very little naloxone reaches the bloodstream, so what the patient feels are the effects of the buprenorphine. However, if naloxone is injected, it can cause a person dependent on a full opioid agonist to quickly go into withdrawal
SUBOXONE® at the appropriate dose may be used to:
- Reduce illicit opioid use
- Help patients stay in treatment by
- Suppressing symptoms of opioid withdrawal
- Decreasing cravings for opioids
Stopping the use of heroin or painkillers is an important step in the treatment of opioid dependence. However, it is only the first step—the next step is not starting again.
Reducing the risk of relapse is actually something that opioid-dependent patients learn how to do. Helping patients to develop the skills to avoid the triggers and situations that might put them at risk is one of the key functions of counseling during treatment. Numerous studies have shown that long-term treatment success (ie, stopping any use of drugs of abuse) is more likely when patients regularly participate in counseling as part of their opioid dependence treatment. For further information on SUBOXONE® go to www.suboxone.com.
For information on the treatment protocol designed for your specific medical needs, contact RCMA at 856-227-2104